文献速递中医儿科中药与中成药合理使用

麦冬二氢高异黄酮B治疗肺炎支原体感染小鼠咳嗽的疗效

The efficacy of ophiopogonanone B in treating the cough in mice infected with Mycoplasma pneumoniae.
PubMed 文献 · Front Pharmacol · 2025-03-26

本研究探讨麦冬二氢高异黄酮B对肺炎支原体感染小鼠咳嗽及肺组织TRPA1、SP、CGRP表达的影响。采用UPLC-Q-TOF-MS检测、分子对接及动物实验,发现该化合物与TRPA1强效特异性结合,高中剂量可显著降低TRPA1、SP、CGRP蛋白及mRNA表达(P<0.01或P<0.05),并减轻肺组织病理改变,从而缓解感染后咳嗽。

要点

  • 麦冬二氢高异黄酮B与TRPA1具有强效特异性结合亲和力。
  • 高中剂量可显著降低肺炎支原体感染小鼠肺组织TRPA1、SP、CGRP表达。
  • 该化合物可改善肺组织形态结构,缓解感染后咳嗽症状。

核心结论

  • 麦冬二氢高异黄酮B通过降低肺炎支原体感染小鼠肺组织中TRPA1、SP和CGRP的表达,有效缓解感染后咳嗽症状。

研究设计与样本

  • 动物实验研究:采用UPLC-Q-TOF-MS检测麦冬二氢高异黄酮B,分子对接分析其与TRPA1结合,并对肺炎支原体感染小鼠肺组织进行HE和Masson染色、免疫组化及RT-PCR检测。

主要发现

  • Biacore fishing结合UPLC-Q-TOF-MS确认麦冬二氢高异黄酮B存在,且与TRPA1具有强效特异性结合亲和力。
  • HE和Masson染色显示麦冬二氢高异黄酮B治疗组肺组织形态结构接近空白组。
  • 免疫组化和RT-PCR显示高中剂量麦冬二氢高异黄酮B治疗组小鼠肺组织TRPA1、SP、CGRP蛋白及mRNA表达显著降低(P<0.01或P<0.05)。

临床怎么用

  • 麦冬二氢高异黄酮B可能通过调控TRPA1/SP/CGRP通路缓解肺炎支原体感染后咳嗽,为含该成分的浓缩丸(如芩白清肺浓缩丸)的临床应用提供实验依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ophiopogonanone B is a potent component of Qinbai Qingfei-concentrated pills (Qinbai), a new traditional Chinese medicine developed by our hospital for the treatment of Mycoplasma pneumoniae pneumonia in children. We aim to study how ophiopogonanone B influences the expression of transient receptor potential anchor protein 1 (TRPA1), substance P (SP), and calcitonin gene-related peptide (CGRP) to treat coughing in MP-infected mice. METHODS: Ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was used to detect ophiopogonanone B. Molecular docking of ophiopogonanone B with TRPA1 was performed using Autodock Vina 1.1.2, and subsequent visualization and analysis of docking outcomes were facilitated using Pymol 2.1 and Discovery Studio. For the evaluation of the pathological structure and morphology, lung tissue sections from mice were prepared for animal experiments and subjected to hematoxylin-eosin (HE) and Masson staining. The impact of ophiopogonanone B on the protein and mRNA expression levels of TRPA1, SP, and CGRP in mouse lung tissue was assessed using immunohistochemistry and real-time polymerase chain reaction (RT-PCR). RESULTS: The samples acquired through Biacore fishing, which were identified and analyzed by UPLC-Q-TOF-MS, confirmed the presence of ophiopogonanone B. This compound exhibited robust and specific binding affinity for TRPA1. Histological staining using HE and Masson techniques revealed that the lung tissue morphology and structure in the ophiopogonanone B-treated group closely mirrored those observed in the blank group. Subsequent immunohistochemistry and RT-PCR revealed a significant reduction (P < 0.01 or P < 0.05) in the proteins and mRNA expression levels of TRPA1, SP, and CGRP in the lung tissue of mice treated with high and medium doses of ophiopogonanone B. CONCLUSION: By decreasing the expression of TRPA1, SP, and CGRP in the lung tissues of mice afflicted with coughing due to M. pneumoniae infection, ophiopogonanone B effectively alleviated post-infection cough symptoms.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu NN, Guo BH, Wang L, et al. The efficacy of ophiopogonanone B in treating the cough in mice infected with Mycoplasma pneumoniae. Front Pharmacol. 2025. PMID: 40206065. doi:10.3389/fphar.2025.1397543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。